Alafuro Oruene, MD
Interventional Pain Medicine · Las Vegas, NVNPI 1649230491
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,666 of the $5,526 with a category attached, or 66.3%. It is spread thinly across 36 manufacturers, the largest accounting for just 22.7%. Reporting peaked in 2021 at $2,277 and has fallen 64.4% since, to $810 in 2025.
Across 179 payments — averaging $30.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biohaven Pharmaceuticals, Inc.$1K
- Redhill Biopharma Inc.$700
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$576
- Forte Bio-pharma LLC$456
- Pfizer$392
- Stimwave Technologies Incorporated$388
- plus $2K from 30 others
What the payments were for
- Consulting fees$1,86034%
- Food & beverage$3,66666%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biohaven Pharmaceuticals, Inc. | 5 | $1,256 |
| Redhill Biopharma Inc. | 3 | $700 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 29 | $576 |
| Forte Bio-pharma LLC | 14 | $456 |
| Pfizer | 31 | $392 |
| Stimwave Technologies Incorporated | 4 | $388 |
| Daiichi Sankyo Inc. | 20 | $213 |
| AbbVie(2 entities) | 8 | $165 |
| Biohaven Pharmaceutical Holding Company Ltd. | 8 | $151 |
| AstraZeneca | 5 | $143 |
| Novo Nordisk | 8 | $143 |
| Abbott | 2 | $134 |
| Nalu Medical, Inc. | 3 | $76 |
| Scilex Pharmaceuticals Inc. | 5 | $72 |
| Merz North America, Inc. | 2 | $63 |
| Alnylam Pharmaceuticals Inc. | 2 | $58 |
| Collegium Pharmaceutical, Inc. | 3 | $56 |
| Lilly USA, LLC | 3 | $54 |
| Bayer | 2 | $41 |
| Vanda Pharmaceuticals Inc. | 1 | $36 |
| Kyowa Kirin, Inc. | 2 | $34 |
| Shionogi Inc | 2 | $34 |
| Dexcom, Inc. | 2 | $32 |
| Biodelivery Sciences International, Inc. | 2 | $30 |
| SPR Therapeutics, Inc | 2 | $28 |
| Boston Scientific | 1 | $27 |
| Ultragenyx Pharmaceutical Inc. | 1 | $22 |
| Inogen, Inc. | 1 | $22 |
| Corcept Therapeutics | 1 | $19 |
| Averitas Pharma Inc. | 1 | $18 |
| Galderma Laboratories, L.p. | 1 | $18 |
| Biotronik NRO, Inc. | 1 | $17 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $17 |
| Medtronic | 1 | $16 |
| Amgen | 1 | $16 |
| Electronic Waveform Lab, Inc. | 1 | $3 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NURTEC ODT$1,200
- MOVANTIK$660
- Prolate$515
- Nalocet$129
- Proclaim IPG$105
How this compares
$5,526 in reported general payments places this provider in the 65th percentile of 32 interventional pain medicine providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 724 | $74,731 |
| Oxymorphone Hcl ErOxymorphone Hcl | 27 | $31,498 |
| RelistorMethylnaltrexone Bromide | 11 | $26,789 |
| OxycontinOxycodone Hcl | 36 | $17,072 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 500 | $16,209 |
| Oxycodone Hcl | 189 | $3,346 |
| Lidocaine | 15 | $3,195 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 39 | $2,325 |
| Morphine Sulfate ErMorphine Sulfate | 99 | $2,002 |
| Gabapentin | 158 | $1,773 |
| Methadone Hcl | 49 | $955 |
| Cyclobenzaprine Hcl | 102 | $780 |
| Pregabalin | 51 | $704 |
| Methocarbamol | 38 | $631 |
| Morphine Sulfate | 14 | $379 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor | $576 | $26,78911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 32 interventional pain medicine providers in Nevada.
Other interventional pain medicine in Las Vegas
- Adam AntflickLas Vegas$26K
- Stephen GephardtLas Vegas$14K
- Jeremy LipshutzLas Vegas$13K
- Denys GoloshchapovLas Vegas$11K
- Edson ErkulvrawatrLas Vegas$6K
- Dolue EzeanolueLas Vegas$5K
- Katherine TravnicekLas Vegas$5K
- Godwin MadukaLas Vegas$4K
- Daniel BurkheadLas Vegas$4K
- Haroon AndarLas Vegas$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.